Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Determinants of Early Mortality Among 37,568 Patients With Colon Cancer Who Participated in 25 Clinical Trials From the Adjuvant Colon Cancer Endpoints Database.

Cheung WY, Renfro LA, Kerr D, de Gramont A, Saltz LB, Grothey A, Alberts SR, Andre T, Guthrie KA, Labianca R, Francini G, Seitz JF, O'Callaghan C, Twelves C, Van Cutsem E, Haller DG, Yothers G, Sargent DJ.

J Clin Oncol. 2016 Apr 10;34(11):1182-9. doi: 10.1200/JCO.2015.65.1158. Epub 2016 Feb 8.

2.

The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.

Cheung WY, Shi Q, O'Connell M, Cassidy J, Blanke CD, Kerr DJ, Meyers J, Van Cutsem E, Alberts SR, Yothers G, Sargent DJ; ACCENT Collaborative Group.

Clin Colorectal Cancer. 2013 Sep;12(3):179-87. doi: 10.1016/j.clcc.2013.04.004. Epub 2013 Jun 27.

3.

Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.

Yothers G, Sargent DJ, Wolmark N, Goldberg RM, O'Connell MJ, Benedetti JK, Saltz LB, Dignam JJ, Blackstock AW; ACCENT Collaborative Group.

J Natl Cancer Inst. 2011 Oct 19;103(20):1498-506. doi: 10.1093/jnci/djr310. Epub 2011 Oct 12.

4.

ACCENT-based web calculators to predict recurrence and overall survival in stage III colon cancer.

Renfro LA, Grothey A, Xue Y, Saltz LB, André T, Twelves C, Labianca R, Allegra CJ, Alberts SR, Loprinzi CL, Yothers G, Sargent DJ; Adjuvant Colon Cancer Endpoints (ACCENT) Group.

J Natl Cancer Inst. 2014 Oct 29;106(12). pii: dju333. doi: 10.1093/jnci/dju333. Print 2014 Dec.

5.

Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.

Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Thomas J, Nelson H, Whittom R, Hantel A, Schilsky RL, Fuchs CS.

J Clin Oncol. 2006 Aug 1;24(22):3535-41. Epub 2006 Jul 5.

PMID:
16822843
6.

Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.

Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, Zhao HW, Chen W, He YL, Wang HY, Xie D, Luo JH.

Lancet Oncol. 2013 Dec;14(13):1295-306. doi: 10.1016/S1470-2045(13)70491-1. Epub 2013 Nov 13. Erratum in: Lancet Oncol. 2014 Jan;15(1):e4.

PMID:
24239208
7.

Nomograms for predicting survival and recurrence in patients with adenoid cystic carcinoma. An international collaborative study.

Ganly I, Amit M, Kou L, Palmer FL, Migliacci J, Katabi N, Yu C, Kattan MW, Binenbaum Y, Sharma K, Naomi R, Abib A, Miles B, Yang X, Lei D, Bjoerndal K, Godballe C, Mücke T, Wolff KD, Fliss D, Eckardt AM, Chiara C, Sesenna E, Ali S, Czerwonka L, Goldstein DP, Gil Z, Patel SG.

Eur J Cancer. 2015 Dec;51(18):2768-76. doi: 10.1016/j.ejca.2015.09.004. Epub 2015 Nov 19.

8.

Nomogram Predicting Survival After Recurrence in Patients With Stage I to III Colon Cancer: A Nationwide Multicenter Study.

Kawai K, Nozawa H, Hata K, Kiyomatsu T, Tanaka T, Nishikawa T, Sugihara K, Watanabe T.

Dis Colon Rectum. 2018 Sep;61(9):1053-1062. doi: 10.1097/DCR.0000000000001167.

PMID:
30086054
9.

Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.

Dignam JJ, Polite BN, Yothers G, Raich P, Colangelo L, O'Connell MJ, Wolmark N.

J Natl Cancer Inst. 2006 Nov 15;98(22):1647-54.

PMID:
17105987
10.

Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy.

Sinicrope FA, Foster NR, Yothers G, Benson A, Seitz JF, Labianca R, Goldberg RM, Degramont A, O'Connell MJ, Sargent DJ; Adjuvant Colon Cancer Endpoints (ACCENT) Group.

Cancer. 2013 Apr 15;119(8):1528-36. doi: 10.1002/cncr.27938. Epub 2013 Jan 10.

11.

Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.

Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Hu FB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS.

JAMA. 2007 Aug 15;298(7):754-64.

PMID:
17699009
12.

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ.

J Natl Cancer Inst. 2011 Jun 8;103(11):863-75. doi: 10.1093/jnci/djr153. Epub 2011 May 19. Erratum in: J Natl Cancer Inst. 2011 Nov 2;103(21):1639. Kim, George P [added].

13.

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J, Labianca R, Chen W, Cha SS, Heldebrant MP, Goldberg RM.

J Clin Oncol. 2004 May 15;22(10):1797-806. Epub 2004 Apr 5.

PMID:
15067028
14.

Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.

Shah MA, Renfro LA, Allegra CJ, André T, de Gramont A, Schmoll HJ, Haller DG, Alberts SR, Yothers G, Sargent DJ.

J Clin Oncol. 2016 Mar 10;34(8):843-53. doi: 10.1200/JCO.2015.63.0558. Epub 2016 Jan 25.

15.

Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.

Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S, Yothers G, Haller D.

Lancet Oncol. 2014 Dec;15(13):1481-92. doi: 10.1016/S1470-2045(14)70486-3. Epub 2014 Nov 12.

16.

Survival following early-stage colon cancer: an ACCENT-based comparison of patients versus a matched international general population†.

Renfro LA, Grothey A, Kerr D, Haller DG, André T, Van Cutsem E, Saltz L, Labianca R, Loprinzi CL, Alberts SR, Schmoll H, Twelves C, Yothers G, Sargent DJ; Adjuvant Colon Cancer Endpoints (ACCENT) Group; Adjuvant Colon Cancer Endpoints ACCENT Group.

Ann Oncol. 2015 May;26(5):950-8. doi: 10.1093/annonc/mdv073. Epub 2015 Feb 19.

17.

Dietary glycemic load and cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.

Meyerhardt JA, Sato K, Niedzwiecki D, Ye C, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Wigler DS, Venook A, Fuchs CS.

J Natl Cancer Inst. 2012 Nov 21;104(22):1702-11. doi: 10.1093/jnci/djs399. Epub 2012 Nov 7.

18.

Individualized prediction of colon cancer recurrence using a nomogram.

Weiser MR, Landmann RG, Kattan MW, Gonen M, Shia J, Chou J, Paty PB, Guillem JG, Temple LK, Schrag D, Saltz LB, Wong WD.

J Clin Oncol. 2008 Jan 20;26(3):380-5. doi: 10.1200/JCO.2007.14.1291.

PMID:
18202413
19.

Individualized prediction of risk of metachronous peritoneal carcinomatosis from colorectal cancer.

Segelman J, Akre O, Gustafsson UO, Bottai M, Martling A.

Colorectal Dis. 2014 May;16(5):359-67. doi: 10.1111/codi.12552.

PMID:
24410859

Supplemental Content

Support Center